Other languages RAPT Therapeutics, Inc.

Equities

RAPT

US75382E1091

Market Closed - Nasdaq Other stock markets 01:30:00 01/05/2024 am IST			5-day change	1st Jan Change
7.7 ^USD	-2.28%		-3.75%	-69.01%

09/04	RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients	CI
27/03	JPMorgan Lowers RAPT Therapeutics' Price Target to $13 From $15, Keeps Neutral Rating	MT

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients	09/04
RAPT Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
RAPT Therapeutics Shares Decline Following UBS Downgrade	23/02
Sector Update: Health Care Stocks Lower Late Afternoon	21/02
Top Midday Decliners	21/02
FDA puts on hold two Rapt Therapeutics mid-stage drug trials	20/02
RAPT Therapeutics, Inc. Announces FDA Verbally Notifies Clinical Hold on its Phase 2b Trial of Zelnecirnon in Atopic Dermatitis and its Phase 2a Trial in Asthma	20/02
RAPT Therapeutics, Inc. Appoints Nipun Davar as Senior Vice President of Technical Operations	13/02
RAPT Therapeutics, Inc. Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon to Treat Atopic Dermatitis in Allergy	27/11
RAPT Therapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	13/11
RAPT Therapeutics Shares Jump After Positive Data From Phase 2 Trial of FLX475 Plus Pembrolizumab in Cancer Patients	03/11
RAPT Therapeutics, Inc. Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC	03/11
RAPT Therapeutics Files for Shelf Offering	11/23/11
RAPT Therapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	11/23/11
RAPT Therapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	11/23/11
RAPT Therapeutics Starts Mid-Stage Trial in Moderate-to-Severe Asthma	29/23/29
Top Midday Decliners	14/23/14
RAPT Therapeutics' Shares Drop Tuesday Afternoon After Q4 Loss Widens	14/23/14
Sector Update: Health Care Stocks Gain Premarket Tuesday	14/23/14
RAPT Therapeutics' Q4 Loss Widens; Shares Down Pre-Bell	14/23/14

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages RAPT Therapeutics, Inc.

Equities

RAPT

US75382E1091

Other languages

Filters